Tango Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $3.53B
- P/E (TTM)
- –
- Dividend yield
- –
About Tango Therapeutics
Pharmaceutical Preparations, SIC 2834
Tango Therapeutics, Inc. is a precision oncology company focused on the development of novel therapies for patients diagnosed with genetically defined or biomarker-driven cancers. Utilizing synthetic lethal targeting designed to spare normal cells, the company discovers and advances oncology treatments targeting pathways such as MTAP-deleted cancers. Its clinical and research programs include therapeutic candidates such as vopimetostat (TNG462), TNG456, and other targeted molecules, which it develops as single agents or in combination therapies alongside strategic collaborators.
The company operates in the United States and maintains its principal executive offices in Boston, Massachusetts. Its facilities include leased properties located at 201 Brookline Avenue. Tango Therapeutics engages with clinical trial sites, research organizations, and manufacturing partners across domestic jurisdictions to advance its preclinical and clinical-stage pharmaceutical pipeline.
Summary of the business section of Tango Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Tango Therapeutics, Inc.
- Founded
- 2020
- Headquarters
- Boston, MA
- Address
- 201 Brookline Avenue, Suite 901 02215
- Phone
- (857) 320-4900
- Website
- tangotx.com
- Employees
- 137, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- TNGX
- Exchange
- Nasdaq
- IPO date
- Sep 4, 2020
- Shares outstanding
- 169M, Aug 4, 2026
- Public float
- $528.40M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 5-for-2, Nov 9, 2021
- SEC CIK
- 1819133
- CUSIP
- 87583X109
- ISIN
- US87583X1090
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Barbara Weber | Director, Executive Chair | 1,629,587 |
| Malte Peters | President & CEO, Director | 367,500 |
| Jessica Newcomb | Principal Accounting Officer | 66,621 |
| Adam Crystal | President, R&D | 142,743 |
| Matthew Gall | Chief Financial Officer | 40,000 |
| Daniella Beckman | Chief Financial Officer | 184,297 |
| Douglas Barry | General Counsel | 66,014 |
| Robert Azelby | Director | 5,740 |
| Mace Rothenberg | Director | 41,500 |
| Sung Lee | Director | 22,870 |
| John B. Ketchum | Director | 24,937 |
| Lesley Ann Calhoun | Director | 16,500 |
| Alexis Borisy | Director | 17,500 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $2.82M | $10.11M | $1.44M | – | – |
| FY2024 | $6.54M | -$3.08M | $3.01M | – | – |
| FY2023 | $3.39M | $8.14M | $2.13M | – | – |
| FY2022 | $4.68M | -$2.85M | $1.67M | – | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 137 full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Aug 13, 2021 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Aug 13, 2021 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Aug 9, 2021 | Name change | Name changed from BCTG Acquisition Corp. to Tango Therapeutics, Inc. |
| Apr 20, 2021 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Sep 4, 2020 | IPO | Initial public offering priced (424B4 prospectus) |
| Sep 2, 2020 | Listing | Registration of securities on an exchange (Form 8-A) |